{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:03:49Z","timestamp":1787504629380,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMW","doi-asserted-by":"publisher","award":["733050206"],"award-info":[{"award-number":["733050206"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["ToBike4Alzheimer"],"award-info":[{"award-number":["ToBike4Alzheimer"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Frontotemporal dementia (FTD) is caused by frontotemporal lobar degeneration (FTLD), characterized mainly by inclusions of Tau (FTLD-Tau) or TAR DNA binding43 (FTLD-TDP) proteins. Plasma biomarkers are strongly needed for specific diagnosis and potential treatment monitoring of FTD. We aimed to identify specific FTD plasma biomarker profiles discriminating FTD from AD and controls, and between FTD pathological subtypes. In addition, we compared plasma results with results in post-mortem frontal cortex of FTD cases to understand the underlying process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Plasma proteins (n\u2009=\u20091303) from pathologically and\/or genetically confirmed FTD patients (n\u2009=\u200956; FTLD-Tau n\u2009=\u200916; age\u2009=\u200958.2\u2009\u00b1\u20096.2; 44% female, FTLD-TDP n\u2009=\u200940; age\u2009=\u200959.8\u2009\u00b1\u20097.9; 45% female), AD patients (n\u2009=\u200957; age\u2009=\u200965.5\u2009\u00b1\u20098.0; 39% female), and non-demented controls (n\u2009=\u2009148; 61.3\u2009\u00b1\u20097.9; 41% female) were measured using an aptamer-based proteomic technology (SomaScan). In addition, exploratory analysis in post-mortem frontal brain cortex of FTD (n\u2009=\u200910; FTLD-Tau n\u2009=\u20095; age\u2009=\u200956.2\u2009\u00b1\u20096.9, 60% female, and FTLD-TDP n\u2009=\u20095; age\u2009=\u200964.0\u2009\u00b1\u20097.7, 60% female) and non-demented controls (n\u2009=\u20094; age\u2009=\u200961.3\u2009\u00b1\u20098.1; 75% female) were also performed. Differentially regulated plasma and tissue proteins were identified by global testing adjusting for demographic variables and multiple testing. Logistic lasso regression was used to identify plasma protein panels discriminating FTD from non-demented controls and AD, or FTLD-Tau from FTLD-TDP. Performance of the discriminatory plasma protein panels was based on predictions obtained from bootstrapping with 1000 resampled analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall plasma protein expression profiles differed between FTD, AD and controls (6 proteins;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), but none of the plasma proteins was specifically associated to FTD. The overall tissue protein expression profile differed between FTD and controls (7-proteins;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). There was no difference in overall plasma or tissue expression profile between FTD subtypes. Regression analysis revealed a panel of 12-plasma proteins discriminating FTD from AD with high accuracy (AUC: 0.99). No plasma protein panels discriminating FTD from controls or FTD pathological subtypes were identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified a promising plasma protein panel as a minimally-invasive tool to aid in the differential diagnosis of FTD from AD, which was primarily associated to AD pathophysiology. The lack of plasma profiles specifically associated to FTD or its pathological subtypes might be explained by FTD heterogeneity, calling for FTD studies using large and well-characterize cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40478-022-01458-w","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T05:11:22Z","timestamp":1666415482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Plasma proteome profiling identifies changes associated to AD but not to FTD"],"prefix":"10.1186","volume":"10","author":[{"given":"R. Babapour","family":"Mofrad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. F. W.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. H. H.","family":"Meeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Seelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Koel-Simmelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. H. G. B.","family":"Ramakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. A. M.","family":"Middelkoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. P.","family":"De Deyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A. H. R.","family":"Claassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"van Swieten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bridel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J. M.","family":"Hoozemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. A. L.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,22]]},"reference":[{"issue":"11","key":"1458_CR1","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S1474-4422(05)70223-4","volume":"4","author":"D Neary","year":"2005","unstructured":"Neary D, Snowden J, Mann D (2005) Frontotemporal dementia. Lancet Neurol 4(11):771\u2013780","journal-title":"Lancet Neurol"},{"key":"1458_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fnagi.2013.00006","volume":"5","author":"DJ Irwin","year":"2013","unstructured":"Irwin DJ, Trojanowski JQ, Grossman M (2013) Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer\u2019s disease. Front Aging Neurosci 5:6","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"1458_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00401-012-1029-x","volume":"124","author":"A Sieben","year":"2012","unstructured":"Sieben A, Van Langenhove T, Engelborghs S, Martin J-J, Boon P, Cras P et al (2012) The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol 124(3):353\u2013372. https:\/\/doi.org\/10.1007\/s00401-012-1029-x","journal-title":"Acta Neuropathol"},{"key":"1458_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00401-011-0839-6","volume":"122","author":"KA Josephs","year":"2011","unstructured":"Josephs KA, Hodges JR, Snowden JS, MacKenzie IR, Neumann M, Mann DM et al (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122:137\u2013153","journal-title":"Acta Neuropathol"},{"key":"1458_CR5","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1212\/01.wnl.0000319702.37497.72","volume":"71","author":"H Seelaar","year":"2008","unstructured":"Seelaar H, Kamphorst W, Rosso SM, Azmani A, Masdjedi R, De Koning I et al (2008) Distinct genetic forms of frontotemporal dementia. Neurology 71:1220\u20131226","journal-title":"Neurology"},{"issue":"3","key":"1458_CR6","doi-asserted-by":"publisher","first-page":"f4827","DOI":"10.1136\/bmj.f4827","volume":"347","author":"JD Warren","year":"2013","unstructured":"Warren JD, Rohrer JD, Rossor MN (2013) Frontotemporal dementia. BMJ 347(3):f4827\u2013f4827. https:\/\/doi.org\/10.1136\/bmj.f4827","journal-title":"BMJ"},{"issue":"5","key":"1458_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/11533100-000000000-00000","volume":"24","author":"GD Rabinovici","year":"2010","unstructured":"Rabinovici GD, Miller BL (2010) Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 24(5):375\u2013398","journal-title":"CNS Drugs"},{"key":"1458_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/09540261.2013.769939","volume":"25","author":"M Pose","year":"2013","unstructured":"Pose M, Cetkovich M, Gleichgerrcht E, Ib\u00e1\u00f1ez A, Torralva T, Manes F (2013) The overlap of symptomatic dimensions between frontotemporal dementia and several psychiatric disorders that appear in late adulthood. Int Rev Psychiatry 25:159\u2013167","journal-title":"Int Rev Psychiatry"},{"issue":"1","key":"1458_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/nan.12530","volume":"45","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H, van Swieten JC, Boxer AL, Rohrer JD (2019) Review: Fluid biomarkers for frontotemporal dementias. Neuropathol Appl Neurobiol 45(1):81\u201387","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1458_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nrneurol.2017.75","volume":"13","author":"LH Meeter","year":"2017","unstructured":"Meeter LH, Kaat LD, Rohrer JD, Van Swieten JC (2017) Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol 13:406\u2013419","journal-title":"Nat Rev Neurol"},{"issue":"14","key":"1458_CR11","doi-asserted-by":"publisher","first-page":"e1231","DOI":"10.1212\/WNL.0000000000005261","volume":"90","author":"LHH Meeter","year":"2018","unstructured":"Meeter LHH, Vijverberg EG, Del Campo M, Rozemuller AJM, Donker Kaat L, de Jong FJ et al (2018) Clinical value of neurofilament and phospho-tau\/tau ratio in the frontotemporal dementia spectrum. Neurology 90(14):e1231\u2013e1239","journal-title":"Neurology"},{"key":"1458_CR12","first-page":"505","volume":"1","author":"YAL Pijnenburg","year":"2015","unstructured":"Pijnenburg YAL, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE (2015) Discriminative and prognostic potential of cerebrospinal fluid phosphoTau\/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer\u2019s dement diagnosis. Assess Dis Monit 1:505\u2013512","journal-title":"Assess Dis Monit"},{"issue":"12","key":"1458_CR13","doi-asserted-by":"publisher","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","volume":"5","author":"L Gold","year":"2010","unstructured":"Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN et al (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5(12):e15004","journal-title":"PLoS ONE"},{"issue":"7","key":"1458_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrd3141","volume":"9","author":"AD Keefe","year":"2010","unstructured":"Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9(7):537\u2013550","journal-title":"Nat Rev Drug Discov"},{"issue":"49","key":"1458_CR15","doi-asserted-by":"publisher","first-page":"19971","DOI":"10.1073\/pnas.1213933109","volume":"109","author":"DR Davies","year":"2012","unstructured":"Davies DR, Gelinas AD, Zhang C, Rohloff JC, Carter JD, O\u2019Connell D et al (2012) Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc Natl Acad Sci USA 109(49):19971\u201319976","journal-title":"Proc Natl Acad Sci USA"},{"key":"1458_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jalz.2013.09.016","volume":"10","author":"M Sattlecker","year":"2014","unstructured":"Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S et al (2014) Alzheimer\u2019s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer\u2019s Dement 10:724\u2013734","journal-title":"Alzheimer\u2019s Dement"},{"issue":"11","key":"1458_CR17","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jalz.2019.06.4951","volume":"15","author":"L Shi","year":"2019","unstructured":"Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F et al (2019) Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer\u2019s Dement 15(11):1478\u20131488","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3389\/fnagi.2018.00409","volume":"10","author":"S Westwood","year":"2018","unstructured":"Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN et al (2018) Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result. Front Aging Neurosci 10:409","journal-title":"Front Aging Neurosci"},{"key":"1458_CR19","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1093\/brain\/awg204","volume":"126","author":"SM Rosso","year":"2003","unstructured":"Rosso SM, Kaat LD, Baks T, Joosse M, De Koning I, Pijnenburg Y et al (2003) Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 126:2016\u20132022","journal-title":"Brain"},{"issue":"3","key":"1458_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P (2018) Amsterdam dementia cohort: performing research to optimize care. Perry G, Avila J, Tabaton M, Zhu X, editors. J Alzheimer\u2019s Dis 62(3):1091\u20131111. https:\/\/doi.org\/10.3233\/JAD-170850","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"1","key":"1458_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","volume":"41","author":"WM Van Der Flier","year":"2014","unstructured":"Van Der Flier WM, Pijnenburg YAL, Prins N, Lemstra AW, Bouwman FH, Teunissen CE et al (2014) Optimizing patient care and research: the Amsterdam dementia cohort. J Alzheimer\u2019s Dis 41(1):313\u2013327","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1458_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-014-0254-4","volume":"14","author":"P Aalten","year":"2014","unstructured":"Aalten P, Ramakers IHGB, Biessels GJ, de Deyn PP, Koek HL, OldeRikkert MGM et al (2014) The Dutch Parelsnoer Institute\u2014neurodegenerative diseases; methods, design and baseline results. BMC Neurol 14:1\u20138","journal-title":"BMC Neurol"},{"issue":"7","key":"1458_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34(7):939\u2013939. https:\/\/doi.org\/10.1212\/WNL.34.7.939","journal-title":"Neurology"},{"key":"1458_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12510","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL et al (2021) Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease\u2013related blood-based biomarkers: results from the standardization of Alzheimer\u2019s blood biomarkers (SABB) working group. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz.12510","journal-title":"Alzheimer\u2019s Dement"},{"issue":"7","key":"1458_CR25","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.neurobiolaging.2014.01.007","volume":"35","author":"M Del Campo","year":"2014","unstructured":"Del Campo M, Hoozemans JJM, Dekkers L-L, Rozemuller AJ, Korth C, M\u00fcller-Schiffmann A et al (2014) BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer\u2019s disease. Neurobiol Aging 35(7):1596\u20131604","journal-title":"Neurobiol Aging"},{"key":"1458_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00401-011-0845-8","volume":"122","author":"IRA Mackenzie","year":"2011","unstructured":"Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E et al (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111\u2013113","journal-title":"Acta Neuropathol"},{"key":"1458_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00401-017-1679-9","volume":"134","author":"EB Lee","year":"2017","unstructured":"Lee EB, Porta S, Michael Baer G, Xu Y, Suh ER, Kwong LK et al (2017) Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 134:65\u201378","journal-title":"Acta Neuropathol"},{"key":"1458_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-007-0237-2","volume":"114","author":"NJ Cairns","year":"2007","unstructured":"Cairns NJ, Bigio EH, Mackenzie IRA, Neumann M, Lee VMY, Hatanpaa KJ et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol 114:5\u201322","journal-title":"Acta Neuropathol"},{"key":"1458_CR29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/bioinformatics\/btg382","volume":"20","author":"JJ Goeman","year":"2004","unstructured":"Goeman JJ, Van de Geer S, De Kort F, van Houwellingen HC (2004) A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20:93\u201399","journal-title":"Bioinformatics"},{"key":"1458_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","volume":"16","author":"NJ Ashton","year":"2020","unstructured":"Ashton NJ, Hye A, Rajkumar AP, Leuzy A, Snowden S, Su\u00e1rez-Calvet M et al (2020) An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol 16:265\u2013284","journal-title":"Nat Rev Neurol"},{"key":"1458_CR31","first-page":"86","volume":"2","author":"CE Teunissen","year":"2016","unstructured":"Teunissen CE, Elias N, Koel-Simmelink MJA, Durieux-Lu S, Malekzadeh A, Pham TV et al (2016) Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimer\u2019s dement diagnosis. Assess Dis Monit 2:86\u201394","journal-title":"Assess Dis Monit"},{"issue":"4","key":"1458_CR32","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/acn3.745","volume":"6","author":"EL van der Ende","year":"2019","unstructured":"van der Ende EL, Meeter LH, Stingl C, van Rooij JGJ, Stoop MP, Nijholt DAT et al (2019) Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Ann Clin Transl Neurol 6(4):698\u2013707. https:\/\/doi.org\/10.1002\/acn3.745","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"1458_CR33","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1021\/acs.jproteome.8b00809","volume":"18","author":"L Dayon","year":"2019","unstructured":"Dayon L, Cominetti O, Wojcik J, Galindo AN, Oikonomidi A, Henry H et al (2019) Proteomes of paired human cerebrospinal fluid and plasma: relation to blood-brain barrier permeability in older adults. J Proteome Res 18(3):1162\u20131174. https:\/\/doi.org\/10.1021\/acs.jproteome.8b00809","journal-title":"J Proteome Res"},{"issue":"1","key":"1458_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S et al (2019) Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer\u2019s disease. Acta Neuropathol Commun 7(1):169. https:\/\/doi.org\/10.1186\/s40478-019-0795-2","journal-title":"Acta Neuropathol Commun"},{"key":"1458_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12643","author":"M del Campo","year":"2022","unstructured":"del Campo M, Zetterberg H, Gandy S, Onyike CU, Oliveira F, Udeh-Momoh C et al (2022) New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz.12643","journal-title":"Alzheimer\u2019s Dement"},{"issue":"2","key":"1458_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0769-2625(85)80048-9","volume":"136","author":"MA Ouaissi","year":"1985","unstructured":"Ouaissi MA, Capron A (1985) Fibronectins: structure and functions. Ann l\u2019Inst Pasteur Immunol 136(2):169\u2013185","journal-title":"Ann l\u2019Inst Pasteur Immunol"},{"key":"1458_CR37","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20199356","author":"JM Bader","year":"2020","unstructured":"Bader JM, Geyer PE, M\u00fcller JB, Strauss MT, Koch M, Leypoldt F et al (2020) Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer\u2019s disease. Mol Syst Biol. https:\/\/doi.org\/10.15252\/msb.20199356","journal-title":"Mol Syst Biol"},{"issue":"4","key":"1458_CR38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000252764","volume":"28","author":"A Lema\u0144ska-Perek","year":"2009","unstructured":"Lema\u0144ska-Perek A, Leszek J, Krzyanowska-Golab D, Radzik J, Katnik-Prastowska MI (2009) Molecular status of plasma fibronectin as an additional biomarker for assessment of Alzheimer\u2019s dementia risk. Dement Geriatr Cogn Disord 28(4):338\u2013342","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"2","key":"1458_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/nan.12295","volume":"43","author":"F-X Lepelletier","year":"2017","unstructured":"Lepelletier F-X, Mann DMA, Robinson AC, Pinteaux E, Boutin H (2017) Early changes in extracellular matrix in Alzheimer\u2019s disease. Neuropathol Appl Neurobiol 43(2):167\u2013182","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"1458_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13041-018-0401-8","volume":"11","author":"Y Noda","year":"2018","unstructured":"Noda Y, Kuzuya A, Tanigawa K, Araki M, Kawai R, Ma B et al (2018) Fibronectin type III domain-containing protein 5 interacts with APP and decreases amyloid \u03b2 production in Alzheimer\u2019s disease. Mol Brain 11(1):61. https:\/\/doi.org\/10.1186\/s13041-018-0401-8","journal-title":"Mol Brain"},{"issue":"2","key":"1458_CR41","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3233\/JAD-151155","volume":"52","author":"S Westwood","year":"2016","unstructured":"Westwood S, Leoni E, Hye A, Lynham S, Khondoker MR, Ashton NJ et al (2016) Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly. J Alzheimers Dis 52(2):561\u2013572","journal-title":"J Alzheimers Dis"},{"key":"1458_CR42","doi-asserted-by":"publisher","first-page":"e28527","DOI":"10.1371\/journal.pone.0028527","volume":"6","author":"M Thambisetty","year":"2011","unstructured":"Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y et al (2011) Plasma biomarkers of brain atrophy in Alzheimer\u2019s disease. PLoS ONE 6:e28527","journal-title":"PLoS ONE"},{"key":"1458_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.712545\/full","author":"L Shi","year":"2021","unstructured":"Shi L, Buckley NJ, Bos I, Engelborghs S, Sleegers K, Frisoni GB et al (2021) Plasma proteomic biomarkers relating to Alzheimer\u2019s disease: a meta-analysis based on our own studies. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2021.712545\/full","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"1458_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3233\/JAD-2012-120820","volume":"32","author":"M Cortes-Canteli","year":"2012","unstructured":"Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH (2012) Fibrinogen and altered hemostasis in Alzheimer\u2019s disease. de la Torre J, editor. J Alzheimer\u2019s Dis 32(3):599\u2013608. https:\/\/doi.org\/10.3233\/JAD-2012-120820","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"6","key":"1458_CR45","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.cell.2005.09.032","volume":"123","author":"A Moumen","year":"2005","unstructured":"Moumen A, Masterson P, O\u2019Connor MJ, Jackson SP (2005) hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 123(6):1065\u20131078","journal-title":"Cell"},{"issue":"1","key":"1458_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40478-018-0524-2","volume":"6","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Ma C, Gearing M, Wang PG, Chin L-S, Li L (2018) Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer\u2019s disease. Acta Neuropathol Commun 6(1):19","journal-title":"Acta Neuropathol Commun"},{"key":"1458_CR47","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00401-021-02340-0","volume":"142","author":"A Bampton","year":"2021","unstructured":"Bampton A, Gatt A, Humphrey J, Cappelli S, Bhattacharya D, Foti S et al (2021) HnRNP K mislocalisation is a novel protein pathology of frontotemporal lobar degeneration and ageing and leads to cryptic splicing. Acta Neuropathol 142:609\u2013627","journal-title":"Acta Neuropathol"},{"key":"1458_CR48","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/hmg\/ddx093","volume":"26","author":"D Moujalled","year":"2017","unstructured":"Moujalled D, Grubman A, Acevedo K, Yang S, Ke YD, Moujalled DM et al (2017) TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Hum Mol Genet 26:1732\u20131746","journal-title":"Hum Mol Genet"},{"key":"1458_CR49","first-page":"s3","volume":"9","author":"F Peyvandi","year":"2011","unstructured":"Peyvandi F, Garagiola I, Baronciani L (2011) Role of von Willebrand factor in the haemostasis. Blood Transf 9:s3","journal-title":"Blood Transf"},{"issue":"6","key":"1458_CR50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12603-010-0043-8","volume":"14","author":"BB Yavuz","year":"2010","unstructured":"Yavuz BB, Dede DS, Yavuz B, Cankurtaran M, Halil M, Ulger Z et al (2010) Potential biomarkers for vascular damage in ALzheimer\u2019s disease: thrombomodulin and von Willebrand factor. J Nutr Health Aging 14(6):439\u2013441. https:\/\/doi.org\/10.1007\/s12603-010-0043-8","journal-title":"J Nutr Health Aging"},{"key":"1458_CR51","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/brain\/awv025","volume":"138","author":"T Thomas","year":"2015","unstructured":"Thomas T, Miners S, Love S (2015) Post-mortem assessment of hypoperfusion of cerebral cortex in Alzheimer\u2019s disease and vascular dementia. Brain 138:1059\u20131069","journal-title":"Brain"},{"issue":"1","key":"1458_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-23865-7","volume":"8","author":"FJ Wolters","year":"2018","unstructured":"Wolters FJ, Boender J, De Vries PS, Sonneveld MA, Koudstaal PJ, De Maat MP et al (2018) Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population-based study. Sci Rep 8(1):1\u201310","journal-title":"Sci Rep"},{"key":"1458_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12415","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Aakre JA, Algeciras-Schimnich A, Proctor NK, Machulda MM, Eichenlaub U et al (2021) Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz.12415","journal-title":"Alzheimer\u2019s Dement"},{"key":"1458_CR54","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L et al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med 26:387\u2013397","journal-title":"Nat Med"},{"key":"1458_CR55","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE et al (2020) Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26:379\u2013386","journal-title":"Nat Med"},{"issue":"23","key":"1458_CR56","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1212\/WNL.0b013e318200d78d","volume":"75","author":"WT Hu","year":"2010","unstructured":"Hu WT, Chen-Plotkin A, Grossman M, Arnold SE, Clark CM, Shaw LM et al (2010) Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology 75(23):2079\u20132086. https:\/\/doi.org\/10.1212\/WNL.0b013e318200d78d","journal-title":"Neurology"},{"issue":"1","key":"1458_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","volume":"119","author":"IRA Mackenzie","year":"2010","unstructured":"Mackenzie IRA, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119(1):1\u20134","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1458_CR58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","volume":"33","author":"L Bu\u00e9e","year":"2000","unstructured":"Bu\u00e9e L, Bussi\u00e8re T, Bu\u00e9e-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work. Brain Res Rev 33(1):95\u2013130","journal-title":"Brain Res Rev"},{"issue":"2","key":"1458_CR59","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0197-4580(98)00022-0","volume":"19","author":"P Davies","year":"1998","unstructured":"Davies P, Resnick J, Resnick B, Gilman S, Growdon JH, Khachaturian ZS et al (1998) Consensus report of the Working Group on: \u201cmolecular and biochemical markers of Alzheimer\u2019s disease\u201d. The Ronald and Nancy Reagan Research Institute of the Alzheimer\u2019s Association and the National Institute on Aging Working Group. Neurobiol Aging 19(2):109\u2013116","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1458_CR60","doi-asserted-by":"publisher","first-page":"48","DOI":"10.15252\/emmm.201708202","volume":"10","author":"ME Umoh","year":"2018","unstructured":"Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI et al (2018) A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10(1):48\u201362","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1458_CR61","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JAD-200110","volume":"76","author":"M Chen","year":"2020","unstructured":"Chen M, Xia W (2020) Proteomic profiling of plasma and brain tissue from Alzheimer\u2019s disease patients reveals candidate network of plasma biomarkers. J Alzheimers Dis 76(1):349\u2013368","journal-title":"J Alzheimers Dis"},{"key":"1458_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-020-00384-6","volume":"15","author":"H Wang","year":"2020","unstructured":"Wang H, Dey KK, Chen PC, Li Y, Niu M, Cho JH et al (2020) Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer\u2019s disease. Mol Neurodegener 15:1\u201320","journal-title":"Mol Neurodegener"},{"issue":"4","key":"1458_CR63","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","volume":"78","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodr\u00edguez J, Snellman A et al (2021) Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol 78(4):396\u2013406","journal-title":"JAMA Neurol"},{"key":"1458_CR64","unstructured":"SomaLogic Inc. SOMAscan technical note"},{"key":"1458_CR65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41576-020-0268-2","volume":"22","author":"K Suhre","year":"2021","unstructured":"Suhre K, McCarthy MI, Schwenk JM (2021) Genetics meets proteomics: perspectives for large population-based studies. Nat Rev Genet 22:19\u201337","journal-title":"Nat Rev Genet"},{"issue":"6","key":"1458_CR66","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1093\/brain\/awaa018","volume":"143","author":"S Ducharme","year":"2020","unstructured":"Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, van den Stock J et al (2020) Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain 143(6):1632\u20131650","journal-title":"Brain"},{"key":"1458_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-020-00736-w","volume":"13","author":"EAJ Willemse","year":"2021","unstructured":"Willemse EAJ, Scheltens P, Teunissen CE, Vijverberg EGB (2021) A neurologist\u2019s perspective on serum neurofilament light in the memory clinic: a prospective implementation study. Alzheimer\u2019s Res Ther 13:1\u201311","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"1","key":"1458_CR68","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s00415-019-09567-8","volume":"267","author":"K Katisko","year":"2020","unstructured":"Katisko K, Cajanus A, J\u00e4\u00e4skel\u00e4inen O, Kontkanen A, Hartikainen P, Korhonen VE et al (2020) Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. J Neurol 267(1):162\u2013167","journal-title":"J Neurol"},{"issue":"1","key":"1458_CR69","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41386-020-00840-3","volume":"46","author":"S Rayaprolu","year":"2021","unstructured":"Rayaprolu S, Higginbotham L, Bagchi P, Watson CM, Zhang T, Levey AI et al (2021) Systems-based proteomics to resolve the biology of Alzheimer\u2019s disease beyond amyloid and tau. Neuropsychopharmacology 46(1):98\u2013115","journal-title":"Neuropsychopharmacology"},{"key":"1458_CR70","doi-asserted-by":"publisher","first-page":"101346","DOI":"10.1016\/j.arr.2021.101346","volume":"69","author":"H Hampel","year":"2021","unstructured":"Hampel H, Nistic\u00f2 R, Seyfried NT, Levey AI, Modeste E, Lemercier P et al (2021) Omics sciences for systems biology in Alzheimer\u2019s disease: state-of-the-art of the evidence. Ageing Res Rev 69:101346","journal-title":"Ageing Res Rev"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-022-01458-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-022-01458-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-022-01458-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T20:04:50Z","timestamp":1666469090000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-022-01458-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,22]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1458"],"URL":"https:\/\/doi.org\/10.1186\/s40478-022-01458-w","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,22]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects gave informed consent according to the declaration of Helsinki (1991), and protocols were approved by local ethical committees at each site participating in this study. All donors (or their next of kin) provided written informed consent for brain autopsy and use of tissue and medical records for research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}